Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 12/20 | 0.50 |
| ▸ | PGR | P06401 | 11/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 11/20 | 0.50 |
| ▸ | AR | P10275 | 11/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6089223 | 0.84 | NR3C1 (0.44) | NR3C1PGRNR3C2ARPLA2G7 | |
| SCHEMBL6092013 | 0.83 | NR3C1 (0.43) | NR3C1PGRNR3C2ARMAPT | |
| SCHEMBL6093413 | 0.79 | NR3C2 (0.48) | NR3C1PGRNR3C2ARCA12 | |
| SCHEMBL6090422 | 0.78 | NR3C2 (0.54) | NR3C1PGRNR3C2ARMAPT | |
| SCHEMBL6089002 | 0.78 | NR3C1 (0.56) | NR3C1PGRNR3C2ARPLA2G7 | |
| SCHEMBL6092232 | 0.78 | NR3C1 (0.63) | NR3C1PGRNR3C2ARPLA2G7 | |
| SCHEMBL6091901 | 0.78 | NR3C2 (0.56) | NR3C1PGRNR3C2ARMAPT | |
| SCHEMBL6091345 | 0.77 | NR3C1 (0.48) | NR3C1PGRNR3C2ARPLA2G7 | |
| SCHEMBL6089084 | 0.75 | NR3C2 (0.46) | NR3C1PGRNR3C2ARPLA2G7 | |
| SCHEMBL6089111 | 0.74 | NR3C1 (0.46) | NR3C1PGRNR3C2ARPLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | NR3C1 4/4885PGR 148/4885NR3C2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.